Abbreviations: 1-NBD-glucose, 1-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-1-deoxyglucose; APC, angular pyranocoumarin; BSA, bovine serum albumin; CHO, Chinese hamster ovary; DMEM, Dulbecco's Modified Eagle's Medium; DMSO, Dimethyl sulfoxide; FCFP6, functional connectivity fingerprint of 6 atoms; HBSS, Hanks' Balanced Salt Solution; HI-FBS, heat inactivated fetal bovine serum; hSGLT, human sodium glucose linked transporter; NEAA, nonessential amino acids; P p.-extract, Peucedanum praeruptorum extract; PC, principal components; PCA, principal components analysis/analyses; PCM, proteochemometric; PMD, physicochemical molecular descriptors; SD, standard deviation; SGLT, sodium glucose linked transporter; SGLT1/2, SGLT1 and/or SGLT2; SGLT2/SGLT1-50μmol/L , ratio of SGLT2 to SGLT1 activities with 50 μmol/L inhibitor; SLC, solute carrier; S xc , similarity of compound x to the central cluster compound c; SMILES, simplified molecular-input line-entry specification; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TEER, transepithelial electrical resistance; TMS, Tetramethylsilane; VC, vehicle control. 
| INTRODUC TI ON
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by prolonged hyperglycemia. In healthy individuals, insulin signaling controls blood glucose levels by inducing tissues to absorb glucose from the circulation. In T2DM, peripheral tissues and the liver gradually become insensitive to insulin. The resulting hyperglycemia can induce a range of pathologies, in particular cardiovascular disease. T2DM is a growing pandemic, 1 and there is a need for alternatives to insulin therapy. Powerful glucose-lowering drugs are available for T2DM. 2 However, these can cause hypoglycemia resulting in considerable morbidity and mortality. 3 Glycemic control therapies should therefore prevent both hyperglycemia and hypoglycemia. Accordingly, inhibitors of the Sodium Glucose Linked
Transporters type 1 and 2 (SGLT1 and SGLT2) have emerged as insulin independent antihyperglycemic remedies. [4] [5] [6] [7] SGLTs are members of the superfamily of Solute Carrier transporter proteins (SLC) and are cotransporters of monosaccharides that rely on the concentration gradient of sodium ions to transport molecules across cell membranes. SGLT1 is a high-affinity, low-capacity transporter that absorbs D-glucose in the small intestine.
SGLT2 has a lower affinity, but higher capacity for D-glucose and is expressed in the kidney proximal glomerular tubules where it reabsorbs ≥90% of glucose from the primary urine. 2, 8 The natural glucosylated-dihydrochalcone phloridzin is a recognized SGLT inhibitor, [9] [10] [11] and its glucosuric effect has long been known. 12 Phloridzin was shown to correct hyperglycemia in rats. 13, 14 Oral intake of phloridzin containing apple extracts caused blood glucose lowering and glucosuria in animal and human studies, but phloridzin was not detected in plasma or urine and the glucuronide metabolites of its aglycon phloretin positively correlated with glucosuria. 15, 16 Thus, the hypoglycemic action of phloridzin involves metabolic and systemic effects that are not entirely understood. Furthermore, phloretin was shown to have undesirable bioactivities in vitro, including inhibition of various transporters, inhibition of oxidative phosphorylation and estrogenic activity.
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SGLT2 selective, rapidly absorbed phloridzin analogs were synthesized to prevent discomfort from high colonic glucose due to intestinal SGLT1 inhibition. [18] [19] [20] These gliflozins efficaciously and safely reduced hyperglycemia in humans. 21 While the glucosuria resulting from taking these drugs prevented weight gain or even induced weight loss in T2DM-patients, 6 it can lead to urinary tract infections. 21 Moreover, SGLT2 inhibitors were shown to have a lower efficacy in individuals with impaired renal function. 22 As 40% of T2DM-patients have some degree of nephropathy, these drugs could have a reduced efficacy in individuals who would benefit the most. 7 Alternatively targeting intestinal SGLT1 to inhibit glucose absorption has therefore gained considerable interest. 4, 23, 24 The dual SGLT1/SGLT2 inhibitor sotagliflozin has shown efficacious and safe glycemic control in T2DM patients and healthy individuals. [25] [26] [27] Furthermore, sotagliflozin increased plasma levels of the incretin GLP-1 and the anorexigenic PYY. 28 Recently, a nonabsorbable sotagliflozin analog was developed, LX2761, that acts as a selective SGLT1 inhibitor 29 and improved glycemic control associated with increased circulating GLP-1 in rodents. 30 A natural, moderately active SGLT1 blocker causing no gastrointestinal discomfort would offer a good prophylactic for (pre-) diabetic individuals. 31 This study aimed to identify molecules outside the chemical space of phloridzin and structurally similar glycosides with moderate SGLT1 inhibitory activity. We screened a bioactive compound library, using an in vitro SGLT1 inhibition assay with a fluorescent glucose derivative as substrate. 32 Screening hits were explored by in vitro (re)testing of these and additional structurally similar compounds, on SGLT1 and SGLT2 (SGLT1/2). We identified various structurally diverse, novel natural and synthetic inhibitors of SGLT1/2 in distinct chemical clusters. The dataset of diverse SGLT1/2 inhibitors with varying activity was used to develop an in silico proteochemometric (PCM) SGLT1 screening model. 33 Finally, the activity of an identified novel natural inhibitor and a plant extract containing this compound were tested in a more physiologically relevant setting with SGLT1-expressing Caco-2 cells, 34 and the close glucose analog 14 C-α-methylglucose as substrate. This study provides starting points for the development and optimization of novel SGLT1/2 inhibitors. Fisher Scientific (Breda, The Netherlands). 1-N-(7-Nitrobenz-2-
| MATERIAL S AND ME THODS

| Materials
custom synthesized by Mercachem (Nijmegen, The Netherlands).
Bovine Serum Albumin (BSA), Poly-L-lysine hydrobromide mol. wt.
30 000-70 000, cell culture grade Dimethyl sulfoxide (DMSO) and 24-well transwell plates (Costar) were all acquired from SigmaAldrich Chemie (Zwijndrecht, The Netherlands). 14 C-α-methylglucose was acquired from Perkin Elmer (Groningen, The Netherlands).
The human SGLT1 (hSGLT1) cDNA cloned in the pCMV6-neo vector was purchased from Origene Technologies (Rockville, USA). The human SGLT2 (hSGLT2) cDNA was custom synthesized and cloned into the pcDNA3.1 vector by Thermo Fisher Scientific (Breda,
The Netherlands). Peucedanum praeruptorum extract powder was obtained from Guangzhou Phytochem Sciences (Guangzhou, China).
Deuterated chloroform containing 0.03% (v/v) Tetramethylsilane (TMS) was acquired from Eurisotop (Saint-Aubin, France).
| Compounds
The Spectrum Collection bioactive compound library was obtained from Microsource (Gaylordsville, USA) and its compounds with simplified molecular-input line-entry specification (SMILES) are shown in Table S1 . The additional compounds with their SMILES and suppliers are listed in Table S2 . Stock solutions of 100 mmol/L were prepared in DMSO and stored at −20°C. Care was taken to remove all medium after each wash. Finally, 1-NBD-glucose was extracted from the cells with 100 μL/well isopropanol for 10 minutes at 600 rpm using an orbital shaker. were calculated from n biological replicates as indicated in Table 1 .
| Cell culture
| Generation of stable CHO-hSGLT1 and CHOhSGLT2 cell lines
If applicable, statistical outliers were determined using Grubbs' test (alpha = 0.05) and excluded for calculation of the mean ± SD normalized SGLT1/2 activity and mean ± SD IC 50 -values.
| Cytotoxicity assay
The cytotoxicity of representative SGLT1/2 inhibitors and compounds from the different chemical clusters was tested.
Cytotoxicity was determined using the ToxiLight bioassay kit ac- was set at 0%. The mean cytotoxicity was calculated from n biological replicates (combining CHO-SGLT1 and CHO-SGLT2 data) as indicated in Table S2 . If applicable, statistical outliers were determined using Grubbs' test (alpha = 0.05) and excluded for calculation of the mean ± SD. CHO-SGLT1/2 inhibition assay medium was not stored for all assays and cytotoxicity of some compounds was not analyzed or analyzed for two biological replicates only. Mean values ≥20% were considered toxic (arbitrary threshold). Most compounds showed cytotoxicity values between −20% and 20% of vehicle control. Only quinine showed a mean cytotoxicity value above the 20% threshold, albeit with a high standard deviation (SD), 21 ± 38% (Table S2 ). Non SGLT1 inhibiting stilbenoids from the viniferin-like cluster, but not (+)-ε-viniferin or (−)-ε-viniferin, produced low negative cytotoxicity values ranging from −42% to −89%, as well as the flavonoid glycoside wistin with −51%. 
| Preparation of an APC containing Peucedanum root extract
| NMR sample preparation and data acquisition
Dried P p.-extract and (+)-pteryxin were dissolved in deuterated chloroform with 0.03% (v/v) TMS using an Eppendorf Thermomixer C at room temperature. Subsequently, the samples were centrifuged for 5 minutes at 17 000 g at room temperature and 650 µL of supernatant was transferred to a 5-mm NMR tube for analysis. 1D 1 H-NMR spectra were recorded with a ZG pulse sequence using a Bruker
Avance III HD 700 spectrometer, equipped with a 5-mm BBI probe. Figure 2 . Results are means with SD from biological replicates, or individual measurements. n.a. = not applicable. + = original dataset contained a statistical outlier that was excluded from calculation of the mean and SD.
spectral width of 20 ppm. The data were processed in Topspin v3.5 pl 1 (Bruker BioSpin GmbH, Rheinstetten, Germany). An exponential window function was applied to the free induction decay with a line-broadening factor of 0.15 Hz prior to the Fourier transformation.
Manual phase and baseline correction was applied to all spectra. The spectra were referenced against the methyl signal of TMS (δ 0.0 ppm). Table S2 14 C-α-methylglucose uptake. Basal media were analyzed accordingly to determine transcellular 14 C-α-methylglucose transport. Mean ± SD 14 C-α-methylglucose uptake and transport were calculated from two biological replicates, each consisting of four technical replicates.
| Selection and clustering of SGLT1 screening hits and structurally similar compounds
From the primary Spectrum Collection SGLT1 screening, 30 hits were selected based on commercial availability. Molecules structurally similar to primary hits were identified using public online compound databases (chemspider.com, pubchem.ncbi.nlm.nih.gov/ Pubchem, mcule.
com) and 101 additional compounds were selected based on commercial availability. All 131 compounds were clustered using a Dice fingerprint distance function, 35 on predetermined molecular Functional Connectivity Fingerprint of 6 atoms (FCFP6). The cluster selection method was set on maximum dissimilarity and clusters were recentered to minimize the average distance within a cluster. The maximum distance between cluster centers was set at 0.6. Calculation of FCFP6 values and clustering was done using Pipeline Pilot software v9.2 (BIOVIA, San Diego, USA). Similarity of cluster compounds (x) was expressed as a percentage of the cluster center (c) which was set at 100% S xc (Table S2 ). 
| Principal component analysis of compound clusters and Spectrum Collection compound library
| RE SULTS
| Screening of the Spectrum Collection bioactive compound library for SGLT1 inhibitors
A screening of 1956 compounds from the Spectrum Collection library for SGLT1 inhibitors resulted in identification of 108 primary hits and 1848 noninhibitors at an activity threshold of ≤70% of negative control, corresponding to a hit rate of 5.5%. A complete overview of screened compounds and their SGLT1 inhibitory activity can be found in Table S1 . Table S2 . For means of n = 2 biological replicates SDs are used indicatively. + = original dataset for this compound contained a statistical outlier which was excluded from calculation of the mean and SD 
| Clusters
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| Glycosides
The canonical natural SGLT1/2 inhibitor phloridzin caused the strongest inhibition of all tested compounds on both SGLT1 and SGLT2 ( Figure 2A , Table S2 ). The background 1-NBD-glucose uptake by SGLT1 and by SGLT2 with 50 μmol/L phloridzin was set at 0%, which equaled 100% inhibition. At 5 μmol/L, phloridzin still caused high nonselective inhibition of 91% of SGLT1 and 92% of SGLT2.
Isoliquiritin, a natural dihydrochalcone glucoside like phloridzin showed 46% inhibition of SGLT1 and 24% inhibition of SGLT2 indicating some SGLT1 selectivity (SGLT2/SGLT1-50μmol/L of 1.4). Polydatin, a natural resveratrol glucoside, inhibited SGLT1 and SGLT2 with 46%
and 18% respectively, also indicating a modest SGLT1 selectivity (SGLT2/SGLT1-50μmol/L of 1.5). Prunetin-4-p-galactoside inhibited SGLT1 and SGLT2 with 62% and 12% respectively, demonstrating noteworthy SGLT1 selectivity (SGLT2/SGLT1-50μmol/L of 2.3).
| Angular pyranocoumarins
The cluster of the natural APCs contained compounds that were second to phloridzin regarding SGLT1 inhibitory activity and showed SGLT1 selectivity. Substitution at the 9' and 10' C-atom of the APC backbone with an alkyl or alkene ester of 2 to 5 C-atoms was essential for SGLT1 inhibition, ranging from 89% for (+)-pteryxin to 41%
for one praeruptorin B ( Figure 2B , Table S2 ). For one APC, the ester side chain at C-atom 10' contained a 2,3-dimethyl-2-oxiranecarboxylate group which reduced SGLT1 inhibition to 27%. Selinidin, lacking the alkene substitution at the C-10', showed minimal inhibition of SGLT1 and SGLT2 (12% and 25% respectively). Lomatin and cis-khellactone, which both lack alkene substitutions but have either a hydroxy-group at C-9', or at C-9' and C-10' respectively, displayed no SGLT inhibition. Notably, for several of the SGLT1
inhibiting APCs substituted at C-9' and C-10' with alkyl or alkene ester side chains that inhibited SGLT1 with 50% to 72%, no to minimal inhibition of SGLT2 was observed indicating SGLT1 selectivity
-50μmol/L of 2.6) and praeruptorin E (SGLT2/SGLT1-50μmol/L of 3.1). APCs that showed no inhibition of SGLT1 also did not show SGLT2 inhibition and none of the APCs showed selectivity for SGLT2.
| Trimipramine-like compounds
In the trimipramine-like cluster, bepridil caused the strongest SGLT1 inhibition of 74% and SGLT2 inhibition of 70%, followed by verapamil (SGLT1 61%, SGLT2 59%) ( Figure 2C , Table S2 ). These two compounds were the least similar to the cluster center, with S xc 47% and 49% respectively. Results from a subcluster of most similar compounds suggested that SGLT1 inhibition is strongest with the N,N,2-trimethyl-1-propanamine side chain on trimipramine (43% inhibition) and that inhibition is reduced when methyl groups are removed, as with imipramine (N,N-dimethyl-1-propanamine side chain) (24% inhibition) and desipramine (N-methyl-1-propanamine side chain) (no inhibition). These differences in activity were not observed for SGLT2
inhibition, indicating SGLT2 selectivity with an imipramine SGLT2/ SGLT1-50μmol/L of 0.4 and a desipramine SGLT2/SGLT1-50μmol/L of 0.5.
| Diphenhydramine-like compounds
Most (active) diphenhydramine-like compounds showed similar inhibition of SGLT1 (31%-72%) or SGLT2 (34%-79%). The inhibitory activity is related to two phenyl-ring structures connected via a single C-atom and an extending N-containing alkyl group attached via an O-atom ( Figure 2D , Table S2 ). Accordingly, cloperastine displayed the strongest SGLT1 inhibition of 72%. Caramiphen deviates structurally (S xc of 57%) from the stronger SGLT1 inhibitors in this cluster by a substitution of one of the phenyl groups for a cyclopentyl group and attachment of the N-containing group via an ester bond instead of an O-atom and, notably, showed stronger inhibition of SGLT2 (58%) than of SGLT1 (33%) (SGLT2/SGLT1-50μmol/L of 0.6).
| Trihexyphenidyl-like compounds
Most active trihexyphenidyl-like compounds were good inhibitors of both SGLT1 (43%-69%) and SGLT2 (40%-61%) ( Figure 2E , Table   S2 ). Trihexyphenidyl, the central compound of this cluster, caused a considerable reduction in SGLT1 substrate uptake of 69%. For this cluster, a central 1-phenyl-propan-1-ol structure is important for SGLT inhibition, with the C-1' atom connected to an additional ring structure like cyclohexyl, or bicycloheptenyl, and the C-3' atom connected to an extending N-containing alkyl group, like pyrrolidinyl, piperidine, or diethylamine, as seen for the active diphenhydraminelike compounds. Compounds in this cluster with a lower S xc showed lower SGLT1 inhibition. Minimal differences were observed between SGLT1 or SGLT2 inhibition.
| Bupivacaine-like compounds
The SGLT1 inhibitory activity of the bupivacaine-like compounds is related to the presence of a piperidine group and the length of the attached N-alkyl chain, with inhibitory activity of N-butyl (bupivacaine, 64% inhibition)> N-propyl (ropivacaine, 30% inhibition)> N-methyl (mepivacaine, 11% inhibition) ( Figure 2F , Table S2 ). No difference in inhibition was observed between a 2,6-dimethylphenyl, or a 2,4,6-trimethylphenyl group. Notably, unlike the other compounds in this cluster the structurally least similar compound ritanserin showed selectivity towards SGLT2 with an SGLT2/SGLT1-50μmol/L of 0.3.
| Quinidine-like compounds
Quinidine-like compounds displayed inhibiting activity for both SGLT1 and SGLT2. Quinidine showed stronger SGLT1 inhibitory activity than its stereoisomer quinine, (50% and 24% respectively) ( Figure 2G , Table S2 ). For SGLT2 inhibition, a smaller difference was observed between these stereoisomers (49% and 34% respectively).
Dihydroquinine showed somewhat stronger inhibition than quinine.
| Viniferin-like compounds
Isomers of the resveratrol dimer viniferin demonstrated differential with 35%, but had no effect on SGLT1 (SGLT2/SGLT1-50μmol/L of 0.6).
| SGLT1/2-IC 50 -values of identified novel inhibitors
The inhibitory activity of the most potent compound from relevant clusters was analyzed more accurately by determining IC 50 values for 1-NBD-glucose uptake by SGLT1 and SGLT2 (Table 1) . SGLT1/2-IC 50 values of found novel inhibitors were in the 10-100 μmol/L range.
| Caco-2 SGLT1 inhibition by (+)-pteryxin and Peucedanum praeruptorum extract
The 
| D ISCUSS I ON
We have tested natural and synthetic compounds for inhibition of the SLCs SGLT1/2. Novel inhibitors were identified in chemically H-NMR spectra of (+)-pteryxin (top) and P p.-extract (bottom) dissolved in CDCl 3 (298K). Characteristic signals from (+)-pteryxin are annotated in both spectra using triangles, indicating the presence of (+)-pteryxin in the P p.-extract chemical clusters. All clusters were separate from the cluster of glycosides. Some partially overlapped with each other when visualized with FCFP6-PCA likely because of only minor structural differences between them. Moreover, using t-distributed stochastic neighbor embedding analysis, it was recently confirmed in a related study that the present SGLT1/2 inhibitor dataset is separated in chemical space from the public dataset in the compound database CheMBL. 33, 37, 38 Thus, the current dataset expands the chemical diversity of SGLT1/2 inhibitors.
The SGLT1/2-IC 50 -values of the most potent novel inhibitors were in the 10-100 μmol/L range. For some inhibitors, molecular features related to the inhibitory activity could be identified. To our knowledge, this study is the first to describe natural inhibitors showing (moderate) selectivity for SGLT1 over SGLT2. Cell viability analyses demonstrated that the inhibitory activities were not due to cytotoxicity artifacts (Table S2 ). The activity of the most potent novel natural inhibitor, (+)-pteryxin, and a natural P p.-extract containing this APC, was confirmed in a more physiologically relevant model using human intestinal SGLT1-expressing Caco-2 cells with the glucose analog 14 C-α-methylglucose as model substrate.
SGLT1-mediated transport of the glycoside polydatin, found in grape juice, 39 has been reported. 40 Polydatin ameliorated T2DM
conditions in in vitro and animal models via various downstream mechanisms. [41] [42] [43] Novel SGLT inhibiting glycosides found here are isoliquiritin from Glycyrrhizae radix (Liquorice) and prunetin-4p-galactoside from Dalbergia spinose roxb, which showed some SGLT1 selectivity. Another natural SGLT1 inhibitor identified is the resveratrol dimer (+)-ε-viniferin from the common grape Vitis vinifera. 44, 45 This confirms previous findings of ε-viniferin reducing SGLT1 mediated glucose absorption in porcine jejunum and ileum. 46 Results from the present study add that (+)-ε-viniferin shows moderate selectivity for SGLT1, while (−)-ε-viniferin displays modest but exclusive inhibition of SGLT2.
Other novel natural SGLT1/2 inhibitors identified are the dihydroxy-APCs from Peucedanum plants. These plants have traditionally been indicated for treatment of obesity and hyperglycemia.
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Studies have described possible molecular mechanisms underlying the hypoglycemic effect of APCs or plant extracts containing these compounds, [47] [48] [49] [50] [51] [52] but none of these studies revealed the SGLT1 inhibiting activity. Here, the presence of hydroxy-ester groups on the 9' and 10' C-atom of the APC backbone showed to be essential for SGLT inhibition. Notably, the praeruptorins A, D and E showed selectivity for SGLT1, while praeruptorin B did not.
Quinidine and quinine from cinchona tree bark are widely used antimalarials 53 that showed hitherto unreported SGLT1/2 inhibition. Notably, hypoglycemia is recognized as a comorbidity of malaria with complex multifactorial etiology, including quinine or quinidine induced hyperinsulinemia. [54] [55] [56] Unchanged renal clearance has been shown for quinine, 57 so it could be speculated that these drugs may inhibit intestinal SGLT1 and renal SGLT2, contributing to blood glucose lowering. To our knowledge, no studies have investigated glucosuria upon quinine and quinidine administration to support this hypothesis. Quinine is also used as a flavoring agent in beverages. It can be speculated that at the maximum FDA The antianginal drug bepridil showed SGLT1/2 inhibition here as well. It was tested in T1DM and T2DM patients on antidiabetic medications, but no additional reduction in blood glucose levels was observed. 60 The antiarrhythmic drug verapamil reduced the appar- (Table S4) . 58 We applied a cellular screening assay to analyze the SGLT1/2 inhibitory activity of structurally diverse compounds using the fluo- (Table S5 ). However, these drugs are designed to be rapidly absorbed and further study is required to determine whether effective concentrations are obtained and maintained at the intestinal SGLT1 target site. 58 Possibly, applying a reversed pharmacokinetics optimization approach, these compounds provide a scaffold to develop nonabsorbable SGLT1 inhibitors analogous to the phloridzin-like inhibitor LX2761.
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Moreover, to enhance the potency and selectivity of the identified leads we suggest an active learning strategy based on PCM modeling. 33, 67 This type of modeling incorporates data of both ligand and known protein targets without requiring 3D structural information making it particularly useful as a virtual screening model for transmembrane transporters like SGLT1/2. The PCM model is trained on existing data and used to virtually screen a library of novel compounds (or modified previously identified hits). Subsequently, a selection is made for experimental validation based on a high predicted activity but with a relatively modest probability. 68 This is contrary to ordinary virtual screening wherein data points to be selected have a high predicted activity and probability. Hence, the model is used to identify data points that lead to the highest information gain (exploration) as opposed to identify newly active data points (exploitation). Previously this approach was shown to lead to a quick improvement in biological activity. 69 Accordingly, using the current and a public dataset, a first PCM SGLT1 screening model was developed that effectively predicted moderately active SGLT1 inhibitors outside the chemical space of the training set. 33 We expect further iterations of in silico and in vitro testing to improve this PCM SGLT1 model and the activity of its predicted hits.
In conclusion, we discovered novel natural and synthetic 
